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Rationale & Objective: Longer and more frequent hemodialysis sessions are associated with both 
benefits and harms. However, their relative importance to patients and how they influence acceptability 
for patients have not been quantified. 
Study Design: Discrete-choice experiment in which a scenario followed by 12 treatment choice sets 
were presented to patients in conjunction with varying information about the clinical impact of the 
treatments offered.  
Setting and Participants: Patients with kidney failure treated with maintenance dialysis for ≥1 year in 5 
UK kidney centers. 
Predictors: Length and frequency of hemodialysis sessions, and their prior reported associations with 
survival, quality of life, need for fluid restriction, hospitalization, and vascular access complications. 
Outcomes: Selection of longer (4.5hr) or more frequent hemodialysis (4 sessions per week) regimens 
versus remaining on 3 sessions per week with session lengths of 4 hours.   
Analytical Approach: Multinomial mixed effects logistic regression estimating the relative influence of 
different levels of the predictors on the selection of longer and more frequent dialysis, controlling for 
patient demographic characteristics. 
Results: Among 183 prevalent in-centre haemodialysis patients (mean 4.7 years on dialysis, mean age of 
63.7 years), 38.3% (70/183) always chose to remain on regimens of 3 sessions per week with session 
duration of 4 hours. Depicted associations of increasing survival and quality of life, reduced need for 
fluid restriction, and avoiding additional access complications were all significantly associated with 
choosing longer or more frequent treatment regimes. Younger age, fatigue, previous experience of 
vascular access complications, absence of heart failure, and shorter travel time to dialysis centers were 










of life to avoid regimens of 4 sessions per week or access complications. After applying estimated 
treatment benefits and harms from existing literature, the fully adjusted model revealed that 27.1% 
would choose longer regimens delivered 3 times per week and 34.3% would choose 4hrs 4 times per 
week. Analogous estimates for younger fatigued patients living near their unit were 23.5% and 62.5%, 
respectively. 
Limitations: Estimates were based on stated preferences rather than observed behaviors. Predicted 
acceptance of regimens was derived from data on treatment benefits and harms largely sourced from 
observational studies. 
Conclusions: Predicted acceptance of longer and more frequent HD regimens substantially exceeds their 
use in current clinical practice.  These findings underscore the need for robust data on clinical 
effectiveness of these more intensive regimens and more extensive consideration of patient choice in 
the selection of dialysis regimens. 
 











Longer or four times a week dialysis have been associated with better outcomes, yet their use is limited 
and they are perceived as undesirable to patients. 184 people on dialysis completed a discrete choice 
questionnaire, which presented the association of these longer and more frequent treatments with longer 
survival, less hospitalization, better quality of life, and fewer vascular access complications. Presented 
with available evidence on these associations, 27.1% of patients would choose longer dialysis and 34.3% 
would choose four times a week dialysis, far more than is currently observed in routine practice. Better 













Observational and clinical trial data have shown survival and quality of life advantages for more 
intensive haemodialysis regimens than the four hours three times a week regimens recommended by 
clinical practice guidelines.1 These regimens include longer session length delivered three times a week, 
and four sessions a week. Despite the stated advantages, acceptance of these treatments in routine 
clinical practice and clinical trials suggest that underlying patient preferences and treatment burden may 
be factors influencing a patient’s choice.2 
Through a range of potential mechanisms more intensive dialysis regimens have potential benefits but 
also potential harms such as fatigue, survival, cardiovascular disease and vascular access patency which 
have been identified as core haemodialysis trial outcomes in consensus exercises.3-5 Previous  stated 
preference work has reported on the proportion of patients who might select more intensive 
haemodialysis regimens, but not in the presence of outcome information, which should ideally be 
presented as part of shared decision making, tailored to the characteristics and goals of the individual.6,7 
By eliciting preferences to the possible benefits and harms of a treatment, the relative importance of 
individual trial endpoints for an intervention can be identified.8,9 In addition to further clarity around 
clinically meaningful differences, the potential size of benefit required to meaningfully change 
acceptance of a treatment can be estimated.10 A comprehensive understanding of patient preferences 
could assist in and predicting capacity requirements, and identify groups who need additional education 
or support when recruiting to trials or undertaking shared decisions around treatment.  
Discrete choice experiments (DCEs) have been shown to accurately estimate patient preferences 
towards treatments, by asking patients to consider treatment options while the potential benefits and 
harms of the different treatment options are varied.11 We present a DCE conducted across five centres 
in the United Kingdom, designed to elicit patient preferences towards longer session length as part of a 
three times a week dialysis schedule, four times a week haemodialysis, or remaining on the standard 
three times a week regimen, all delivered in-centre.12,13 Accounting for individual patient characteristics 
which influence these preferences, we estimate the acceptance of these more intensive regimens in the 












This labelled DCE is reported in accordance with ISPOR Good Research Practices publications in this 
area.14,15 The DCE was designed to elicit preferences towards the dialysis regimen choices of longer 
session length delivered three times a week, versus more frequent four times a week haemodialysis, 
versus remaining on three times a week haemodialysis, with the preferences dependent on four 
outcome-based treatment attributes (survival, hospitalisation, quality of life and vascular access 
complications). By asking the respondent to complete multiple choice sets, the relative importance of 
the attributes, their levels, the choices (dialysis regimens) and any trade-offs can be estimated. Detailed 
information for the discrete-choice experiment methodology applied in health care can be found 
elsewhere.15 Ethical approval for the study was obtained in June 2019 (Health Research Authority IRAS 
reference 253384) and the participants were recruited between February 2019 and November 2019. 
Participants and study perspective 
The inclusion criteria for the study were prevalent in-centre haemodialysis patients who had been 
receiving treatment for at least one year. This ensured sufficient experience of in-centre haemodialysis 
to consider and relate to the scenario, and aligned with the informing studies in which the majority of 
patients who received these treatments had been dialysing in excess of one year. 12,13 The exclusion 
criteria were: an existing diagnosis of malignancy (as patients with a limited life-expectancy may not be 
offered these regimens, and may have their treatment shortened towards the end of life)12 or the 
presence of a formal diagnosis of cognitive impairment in the medical notes, or the presence of 
cognitive impairment as assessed by the dialysis nursing staff or the researcher conducting the 
questionnaire. 
The questionnaire booklet begins by asking participants to consider a scenario where they were an in-
centre haemodialysis patient who after two years of treatment had developed high ultrafiltration rates 
and significant fatigue. In the scenario the staff at the dialysis unit hypothetically offer them longer 
sessions (4.5hrs) three times a week,12 more frequent four times a week 4hr duration hemodialysis 13 or 
remain on the current 4hr three times a week treatment (an opt-out choice). The questionnaire then 
asks the participant to consider which haemodialysis regimen they would select in this scenario twelve 
times. With each of the twelve questions (choice sets) the associated benefits and harms (survival, 
hospitalisation, quality of life, fluid restriction and vascular access complications) vary in a prespecified 
manner to build a statistical model of the individual’s preferences (Item S1) 










We presented two, more-intensive regimen choices that were based on published data evaluating these 
treatments in the context of the increased hospitalisation and mortality associated with the long 
interdialytic interval intrinsic to three times a week haemodialysis schedules 16, and that were designed 
to be plausible and available in existing clinical practice. Attributes had all been prioritised in existing 
mixed methods research. In order to predict acceptance, existing evidence between attributes and the 
treatment regimens being offered informed attribute and level selection.7,12,13,17,18  Each of the twelve 
DCE questions included a labelled description of longer, four times a week and continuing three times a 
week haemodialysis and the attributes associated with them for that particular DCE choice set. Table 1 
shows an example of the attributes presented to the patient for the third DCE choice set, which 
illustrates the range of levels each attribute could take: survival (9 years, 10 years, 12 years or 14 years), 
quality of life (you feel the same, you feel better), fluid restriction (you can drink the same, you can drink 
more), hospitalisation (once a year, once every two years) and access complications (no change, more 
complications). All twelve DCE choice sets are presented in Item S1. In order to present absolute years of 
survival for the survival attribute, the survival associated with continuing on standard haemodialysis of 9 
years was estimated using a parametric exponential survival model fitted on the patients with 
ultrafiltration rates of >10ml/kg/hr who continued to receive 3xW HD in an informing analysis.13 This 
model included age, gender, comorbidities, phosphate, dialysis access and ultrafiltration rate as 
adjustment variables. 
Instrument design and sample size 
The goal of the DCE is to build a model from which the relative influence of each of the attributes, and 
anything pertaining to the of the treatments themselves, can be estimated. Undertaking this could 
involve presenting every permutation of the attributes and asking the respondent to select a treatment, 
however this is rarely practical. Fewer DCE questions may result in improved response efficiency (the 
measurement error associated with respondent inattention introduced by too many questions).14 It is 
considered common practice to have between 8 and 16 DCE questions,15 with reviews highlighting 70% 
of studies having 3 to 6 attributes with up to 4 attribute levels.19 A full-choice array containing every 
possible permutation of the attribute levels was generated and from this a D-efficient design was 
identified by sampling subsets of this array. This was performed using the DCREATE command in STATA20 
resulting in a randomly ordered design with 12 DCE questions and a D-efficiency of 1.607. A sample size 










alpha of 0.95, accuracy of 10% and an expected choice proportion of 20%6. This was doubled to 256 to 
allow for subgroup and interaction effects estimation. 
Data collection 
Research nurses and clinical trial assistants screened individuals based on the inclusion criteria then 
approached haemodialysis patients on the dialysis unit for consent to perform the paper questionnaire. 
Often the patient would complete the questionnaire while receiving dialysis and with the researcher 
nearby facilitating assistance when required, in line with ISPOR Good Research Practices.14,15 Following 
an explanation of the decision scenario the respondent undertook a comprehension question that 
presented the treatments with hypothetical benefits and harms in the same format as the rest of the 
DCE, and asked the respondent to state which treatment has the best levels for each of the five 
attributes. The twelve DCE questions were then completed along with some demographic information 
including: the SONG-HD fatigue measure,22 travel time to the dialysis unit, personal experience of 
hemodialysis access problems, if the more intensive regimens had previously been offered and a short 
health literacy question.23 The researchers completed a demographic information from patients notes 
including comorbidities, hemodialysis schedule, dialysis access, haemoglobin and ultrafiltration volume. 
Statistical Analysis 
The differences in patient characteristics according to whether the patient had been previously offered 
more intensive dialysis were statistically assessed using independent T-tests for continuous variables 
and Chi-Squared tests for categorical variables.  
A multinomial logistic model with random coefficients (mixed effects), with the selection of one of the 
treatments as the dependent (outcome) variable was used to estimate the relative influence of different 
levels of the attributes and description of the treatment regimens, with odds ratios (OR) reported.24 A 
mixed model allows for correlated preferences (e.g. a patient having a greater preference for both 
longer and more frequent dialysis), and is fit on data with an observation per treatment offered (e.g. 3 
observations per choice-set). Allowing the constants associated with the descriptions of the treatments 
to vary between respondents provided a superior fit compared to fixed values for all respondents, and 
the standard deviation of all random parameters were significant. The final models were estimated with 
1000 Halton draws.  
Patient characteristics which may influence preferences for attributes and choices were controlled for 










categorical with the demographic variables of age (<50, 50-80 & >80 years), travel time (<30 or >=30 
minutes), time on renal replacement therapy (<2 years, 2-5 years, >5 years) categorised based on their 
distributions. The SONG HD Fatigue measure was calculated based on the sum of questions on feeling 
tired, lacking energy and limits on usual activities individually scored 0-3 (total score 0-9).22 All analyses 
including those with interactions use the opt-out of continuing on three times a week, 4 hours as the 
reference. The best performing model in the presence of interactions was identified using Akaike 
information criterion which penalises for additional co-variates. Using the model with the best 
performance, trade-offs between survival and other attributes and predicted acceptance of treatments 
were estimated. Survival in years was treated as a continuous variable in the model, and using the 
STATA WTP25 command an estimate of the number of years patients would sacrifice to improve other 
attributes or avoid the treatment burden associated with the more intensive regimens was calculated. 
Because individuals who always choose the opt-out (to stay on 3xW 4hrs) have an infinitely large choice 
specific constant for the opt-out alternative potentially resulting in bias, the results of the analysis are 
presented only in those who always chose the opt-out excluded. An analysis on all patients is reported 
in Table S1. Interactions between patient characteristics and choice specific constants were specified as 
fixed effects in all models. The probability of acceptance of the regimens was estimated using the model 
with the best Akaike information criterion: a systematic review which informed UK hemodialysis 
guidelines was updated and effect sizes for the treatment attributes associated with the different 
regimens extracted.1 Applying these effect sizes to estimates of survival, quality of life, fluid restriction 
and access complications to informing literature and the parametric survival estimate identified values 
to set the attributes for each regimen. Acceptance of treatments are reported for the cohort who 
completed the questionnaire, and for patients with specific characteristics determined by those 
included in informing clinical trials4, or clinically relevant subgroups. The attributes from the literature 
(largely observational), alongside more conservative estimates, informed by a reduction by one level of 
any attributes associated with improved outcomes, are detailed in Table 5. 
RESULTS 
Across five centres, 292 patients were approached, of whom 204 consented (69.9%), 196 patients 
returning the questionnaire and 183 completing all 12 DCE questions. The demographics were 
comparable to prevalent in-centre HD patients in the UK and observational studies informing the 
questionnaire. After reading the description of the fictional patient in the opening scenario, 40.2% 










Table 2 reports the overall demography of those completing the questionnaire, and then stratified by 
whether more intensive dialysis had (65/183, 35.5%) or had not been discussed (118/183, 64.5%). 
Overall, 24.7% and 14.8% of patients had previously been approached about longer hours and 4xW HD 
respectively. Patients who had been offered more intensive dialysis were statistically more likely to be 
younger, male, live nearer the renal centre and have had previous dialysis access complications, with a 
tendency to be more comorbid. Feeling that the scenario sounded like them was associated with a 
higher fatigue score (4.9 vs 3.1, P=0.002). 53.6% (97/181) had previously experienced vascular access 
problems. 
23.3% (42/180) of patients incorrectly answered all five of the comprehension tests questions, which did 
not significantly vary with health literacy (P=0.8). 
Treatment and outcome preferences 
From 183 completed 12-question-DCEs resulting in 2,196 choices, longer dialysis sessions were selected 
in 29.3%, more frequent four times a week in 20.4% and continuing on three times a week 
haemodialysis in 50.3%. Increasing quality of life and survival and reduced fluid restriction with a 
regimen all had a clinically plausible positive influence on the selection of a more intensive regimen, 
while increased vascular access complications associated with a regimen reduced the likelihood of a 
regimen’s selection (Table 3). Hospitalisation had no influence. The adjusted odds ratios (e.g. benefits 
and harms set to that of 3xW HD) of selection of longer hours were 0.06 (95% CI 0.02 - 0.14) and for four 
times a week 0.005 (95% CI 0.001 - 0.01). These adjusted values in isolation are only illustrative, as 
patients and clinicians consider offering or accepting these regimens in the presence of benefits and 
harms which are generally more preferable for the revised treatment being offered, rather than the 
same as the current treatment.  These estimates did not significantly differ when limited to individuals 
who got no comprehension test questions wrong (Table S2). 
Interactions between demography, experience, symptoms and choice 
Patients under the age of 50 had a stronger preference for the more intensive regimens, and decreasing 
age was associated with significant increases in how patients valued survival advantages and fluid 
restrictions (Figure 1 & 2). Higher ultrafiltration rates did not modify preferences towards reduced fluid 
restriction (Figure 2). 
Patients who had experienced a vascular access complication found both regimens more acceptable 










dialysis via a fistula rather than a catheter/line was associated with greater preference more intensive 
regimens. The absence of heart failure significantly increased preference for four times a week HD but 
diabetes and previous myocardial infarction had no influence on treatment preference, and there was 
no interaction between comorbidities and the attributes of survival or quality of life. 
Patients who scored less than 4 on the SONG-HD Fatigue measure had very low preference towards four 
times a week haemodialysis, while increasing fatigue was associated with increasing preference towards 
quality of life improvements associated with a regimen, particularly in those scoring >7. There was no 
relationship between higher health literacy, Tuesday/Thursday/Saturday dialysis schedule compared to 
the Monday/Wednesday/Friday schedule, or the number of years treated by haemodialysis and 
preferences towards either more intensive regimen.  
Trading survival for improvements in other attributes 
The fully interacted model (Table S3) resulted in linear increases in the coefficients informing the odds 
ratios for increasing survival in years enabling the estimation of trade-offs between survival and the 
other attributes. The 38.3% (70/183) who always chose to stay on 3xW 4hrs introduced a bias in the 
estimates due to having an infinitely small treatment-specific odds ratio, and following their exclusion 
the following estimates were obtained (Table 4, model reported in Table S3): patients would sacrifice 
approximately 2 years of life to avoid attending four times a week or an access complication, and 
sacrifice more liberal fluid intake or quality of life for an additional two-thirds of a year of survival.  
Projected acceptance of longer or four times a week hemodialysis 
Patient characteristics, hypothesised treatment benefits and model specification influenced the 
proportion of patients who would choose longer dialysis three times a week, four times a week or opt to 
remain on their current treatment (Table 5). Based on the more optimistic treatment benefits, 29.1% 
would dialyse longer, 35.8% would dialyse four times a week and 35.1% remain on their current 
treatment, with these proportions changing to 27.1%, 34.3% and 38.6% respectively when incorporating 
patient characteristics in the model. More conservative benefits generally increased the percentage 
opting to remain on current treatment by approximately 10 percentage points. Simulating a cohort 
comparable to those recruited into the frequent haemodialysis network (FHN) trial, the proportion 
selecting four times a week dialysis was 44.6%. Elderly patients with moderate fatigue who live far from 










proportions for younger severely fatigued patients living nearer the unit were 23.5% and 62.5% 
respectively.  
DISCUSSION 
This multi-centre study used a DCE to estimate preferences towards the benefits and harms associated 
with longer and more frequent in-centre haemodialysis regimens. Improvements in quality of life, 
survival and fluid restriction were associated with selecting a more intensive regimen.  Younger, more 
fatigued patients who were able to do their own blood pressure, pulse and temperature undergoing 
hemodialysis (and perhaps other dialysis-related tasks) were more likely to choose four times a week 
dialysis. However, longer and four times a week haemodialysis could be considered undesirable as 
38.5% of patients completing the DCE did not choose them in any situation, and those who did would 
still sacrifice two years of additional life to avoid them. Despite this, if presented with benefits of these 
regimens from the literature, between half and two-thirds of patients would be willing to be treated 
with dialysis regimens that are 4 times per week or dialyse for longer than 4 hours three times a week. 
Our findings corroborate existing research: 33.5% of US haemodialysis patients who were struggling 
with their fluid restriction said they would dialyse for an additional 30 minutes and 19.6% would do an 
additional weekly session, although the benefits associated with these regimens were not presented. 
Patients from the US study were generally closer to the patient phenotype described in our scenario and 
in whom these interventions are routinely used.6 A study using conjoint analysis identified that 44% of 
sampled patients would not select daily hemodialysis irrespective of the potential health benefits, 
however 38.9% of patients would chose the treatment if the quality of life and survival benefits were 
comparable to those applied to four times a week in our study.26 Both studies found greater acceptance 
in younger, less comorbid patients. The statistical and clinical significance of the attributes of survival, 
quality of life and avoiding vascular access complications,  with the lower importance of hospitalisation, 
align with recent prioritisation exercises for clinical trial endpoints in haemodialysis.18 Direct comparison 
of the predicted acceptance of treatments in our  cohort to other studies is challenging: simulating the 
FHN daily trial cohort who were offered 5-6 sessions a week 37-44% of patients would select 4 times a 
week HD, compared to the 12% of those approached agreeing to participate in the FHN trial. A third of 
patients in our study had been approached about more intensive regimens and real world data suggests 
around 3.5% subsequently receiving four times a week dialysis and 18% receiving 4.5hrs 3xW in clinical 
practice.12,13 Discrepancies between real-world use and predicted uptake could relate to observed and 










statistical models. To tackle the long interdialytic interval, the fourth session should ideally be scheduled 
during this period, although some patients may wish to preserve a 2-day gap. However patients can 
recognise and quantify the potential survival and quality of life benefits associated with an additional 
session during the traditional long interdialytic interval.27  More generally models from DCE studies have 
been shown to have reasonable positive predictive value for choices made in real world clinical 
practice28, but the disproportionate presence of selecting the status quo exists both in this study and 
many others exploring decision-making.29 
The strengths of our study include a strong underlying methodological design to elicit preferences, and 
the presentation of HD regimens which are currently available and for which some estimates of efficacy 
are known. The presented scenario resonated with 78.6% of respondents who had personal experience 
of haemodialysis. The modest sample size exceeding formal power calculations, and where possible 
estimates on subgroups were drawn from interactions, retaining the overall sample size. Weaknesses 
included the assessment of stated preferences and not genuine choices that the patient subsequently 
made, potentially over-optimistic baseline survival estimates for the scenario and that acceptance 
probabilities were informed by largely observational data. A quarter of patients answered all four 
comprehension test questions incorrectly, which may relate to questionnaire complexity or the 
cognitive function of the patient group. 
Findings from our study raise the policy and future research issue that if patient acceptance of these 
treatments is as high has estimated in our study, it is even more important to obtain high quality 
evidence to determine their clinical effectiveness prior to more routine presentation of these regimens 
to patients. The difference between predicted and observed uptake of these treatments suggests there 
are individuals who may be willing to do more HD treatment to access benefits reported in the 
literature, while only a third of this cohort had actually been approached regarding the treatment 
options. The findings do allude to certain groups of patients who are more likely to accept these 
treatments, and could inform models of haemodialysis capacity. Significant increases in uptake could be 
offset by an incremental approach to haemodialysis dosing that would include lower frequency when 
starting dialysis.30 Integral to these decisions around treatment would be the presentation of 
information obtained from generalisable trials of these interventions in HD patients which have been 
challenging to recruit or retain patients, or statistically demonstrate health benefits.2,31,32 This person-
centred shared decision would need to elicit the treatment goals of the patient as prioritised in other 










from our  study, there is an increasing imperative to gain high quality data on the clinical and cost-
effectiveness of these treatment options to advocate for their use with decision-makers and inform 
patients in whom the treatments are indicated. 
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Table 1 – Example of Discrete Choice Experiment choice set (number 3), and different attribute levels 
(14 years survival also presented in other choice sets) 
Description Longer sessions Extra Session No Change 
Frequency 
Three times a 
week 
Four times a week 
Three times a 
week 
Session length 
4 and a half 
hours 
4 hours 4 hours 
Information    
Survival 10 years 12 years 9 years 
Quality of Life 
You feel the 
same 
You feel better 
You feel the 
same 
Fluid Restriction 
You can drink 
the same 
You can drink more 
You can drink the 
same 





No change No change 
 












Table 2 – Patient Demographics 
  Previously offered more intensive dialysis 
 Overall 
Yes (longer 
and/or 4xW) No  
 183 65/183 118/183 P 
Age 63.7 (15.4) 60.1 (16.0) 65.7 (14.7) 0.009 
<50 18.6% (34/183) 23.1% (15/65) 16.1% (19/118)  
50-80 67/2% (123/183) 67.7% (44/65) 66.9% (79/118)   
>80 14.2% (26/183)  9.2% (6/65) 17.0% (20/118)  
Gender 63.4% (116/183) 76.9 (50/65) 55.9 (66/118) 0.005 
Ethnicity (White) 80.3% (147/183) 78.5 (51/65) 81.4 (96/118)  
Comorbidity     
Diabetes 36.6% (67/183) 41.5 (27/65) 33.9 (40/118) 0.3 
Previous Myocardial Infarction 9.3% (17/183) 10.8 (7/65) 8.5 (10/118) 0.6 
Heart Failure 10.4% (19/183) 15.4 (10/65) 7.6 (9/118) 0.1 
Weight 83.4 (25.4) 85.3 (25.3) 82.4 (25.5) 0.8 
Ultrafiltration     
Two day interval (ml/kg/hr) 6.8 (3.2) 6.6 (3.4) 6.9 (3.1) 0.3 
One day interval (ml/kg/hr) 5.2 (2.8) 5.3 (2.8) 5.2 (2.9) 0.6 
Haemoglobin 106.3 (19.7) 108.6 (16.2) 105.1 (21.5) 0.9 
Time on Dialysis (years) 4.3 (4.2) 4.0 (3.4) 4.5 (4.6) 0.2 
<2 years 30.6% (56/186) 27.7% (18/65) 32.2 (38/118)  
2-5 years 41.5% (76/186) 50.8% (33/65) 36.2 (43/118)  
>5 years 27.4% (51/186) 21.5% (14/65) 31.4 (37/118)  
Dialysis Access    0.4 
AVF 72.6% (130/179) 71.9% (46/64) 73.0% (84/115)  
Dialysis Catheter 23.5% (42/179) 25.0% (16/64) 22.6% (26/115)  
Other 3.9% (7/179) 3.1% (2/64) 4.4% (5/115)  
Mon/Wed/Fri Schedule 56.1% (101/180) 65.6% (42/64) 50.9% (59/116) 0.1 
     
SONG HD Fatigue Score 4.9 (2.5) 5.1 (2.7) 4.8 (2.4) 0.2 
<4 35.0% (64/183) 33.9% (22/65)  35.6% (42/118)  
4-7 44.8% (82/183) 44.6% (29/65) 44.9% (53/118)   
>7 20.2% (37/183) 21.5% (14/65) 19.5% (23/118)  
Previous Access Complications 53.6% (97/181) 68.3% (43/63) 45.8% (54/118) 0.004 
Dialysis Travel Time (minutes) 25.0 (16.4) 20.8 (14.0) 27.3 (17.2) 0.005 
Inadequate Health Literacy 15.6% (28/180) 19.4% (12/50) 13.6% (16/118) 0.3 












Table 3 – Adjusted odds ratios from multivariable analysis for the selection of longer and more 
frequent dialysis, presented alongside their potential benefits and harms. 
 Coefficient Odds Ratio P 
Survival    
10 years (+1 yr) 1.01 (0.53 - 1.48) 2.73 (1.7 - 4.39) <0.001 
12 years (+2 yrs) 3.24 (2.64 - 3.84) 25.5 (13.97 - 46.55) <0.001 
14 years (+4 yrs) 3.79 (3.08 - 4.51) 44.36 (21.7 - 90.7) <0.001 
Quality of Life improved 0.4 (0.04 - 0.76) 1.49 (1.04 - 2.14) 0.03 
Fluid Restriction relaxed 0.47 (0.12 - 0.83) 1.61 (1.13 - 2.28) 0.008 
Hospitalisation reduced 0.11 (-0.15 - 0.38) 1.12 (0.86 - 1.46) 0.4 
Access Complications increased -2.12 (-2.63 - -1.62) 0.12 (0.07 - 0.2) <0.001 
    
Longer 3x Week -2.86 (-3.75 - -1.97) 0.06 (0.02 - 0.14) <0.001 
Four times a week -5.39 (-6.54 - -4.24) 0.005 (0.001 - 0.01) <0.001 
Multivariable adjusted coefficients and Odds ratios for dialysis regimens represent the likelihood of 
being selected if there were no benefits or harms compared to 3xWHD. The overall likelihood of a 
treatment being selected can be estimated by the sum of the coefficients for a given treatment. E.g. 
Four times a week resulting in +2 years survival, quality of life improved and fluid restriction relaxed: 












Table 4 – Years of patient survival traded for improvements in other attributes or avoiding 
longer/more frequent dialysis. 
 Years of survival traded 
95% CI 
Longer Three times a week 
-1.03 
 
-2.43 to 0.36 
Four times a week 
1.98 
 
0.29 to 3.67 
Quality of life 
-0.65 
 








1.49 to 2.97 
Interpretation: Negative value – In the absence of other attributes or change in HD regimen (due to multivariable adjustment), 
the number of years survival a patient would give to obtain the attribute. Positive value – the number of years survival a patient 











Table 5 – Probability of acceptance according to patient characteristic and available evidence 
  Standard Estimates Conservative Estimates 
  3xW 4.5hrs 4xW Opt-out 3xW 4.5hrs 4xW Opt out 
Cohort 










































FHN Trial  
Mean age 50 (SD 14), 
Heart Disease 20%, 39% 
on HD for 2-5 years, 
Fatigue VAS 4.7 (SD 2.2), 
42.7% doing own obs, 





















Age 82, Lives far from the 



















Young working age 
patient 
Age 45, Lives near the 




















* Interactions specified: Choice specific constants and the variables age, time on dialysis, heart failure, fatigue, undertaking own observations 











Figure 1 – Treatment specific constant interactions 
























Time on dialysis <2 years
Time on dialysis 2−5 years
Time on dialysis >5 years
Travel to dialysis <30 mins
Travel to dialysis 30min +
SONG Fatigue score <4
SONG Fatigue score 4−7
SONG Fatigue score >=8
Does own obs




Odds Ratio for 4.5hr 3xW Odds Ratio for 4hr 4xW





























Age - 1 Year additonal survival Age - 3 Years additonal survival Age - 5 Years additonal survival
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